Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J Feb 1 2021;42:373-498.

Reddy V.Y. Doshi S.K. Sievert H. Buchbinder M. Neuzil P. Huber K. Halperin J.L. Holmes D. Investigators P.A.

Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.

Circulation Feb 12. 127: 720-729Holmes Jr., D.R. Kar S. Price M.J. Whisenant B. Sievert H. Doshi S.K. Huber K. Reddy V.Y.

Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

J Am Coll Cardiol Jul 8. 64: 1-12

Holmes DR, Jr., Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano M, Reddy VY. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. Journal of the American College of Cardiology Jun 23 2015;65:2614-2623.

Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol Jun 25 2013;61:2551-2556.

Boersma L.V. Ince H. Kische S. et al.

Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage.

Circ Arrhythm Electrophysiol Apr. 12e006841Labori F. Bonander C. Persson J. Svensson M.

Clinical follow-up of left atrial appendage occlusion in patients with atrial fibrillation ineligible of oral anticoagulation treatment-a systematic review and meta-analysis.

J Interv Card Electrophysiol Feb. 13Fauchier L. Cinaud A. Brigadeau F. et al.

Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation.

J Am Coll Cardiol Apr 10. 71: 1528-1536Reddy V.Y. Doshi S.K. Kar S. et al.

5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.

J Am Coll Cardiol. 70: 2964-2975Freeman J.V. Varosy P. Price M.J. Slotwiner D. Kusumoto F.M. Rammohan C. Kavinsky C.J. Turi Z.G. Akar J. Koutras C. Curtis J.P. Masoudi F.A.

The NCDR Left Atrial Appendage Occlusion Registry.

J Am Coll Cardiol Apr 7. 75: 1503-1518Friberg L. Rosenqvist M. Lip G.Y.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

European heart journal Jun. 33: 1500-1510Lip G.Y. Frison L. Halperin J.L. Lane D.A.

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Journal of the American College of Cardiology Jan 11. 57: 173-180Holmes D.R. Reddy V.Y. Turi Z.G. Doshi S.K. Sievert H. Buchbinder M. Mullin C.M. Sick P. Investigators P.A.

Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Lancet. 374: 534-542Boersma L.V. Ince H. Kische S. et al.

Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.

Heart Rhythm Sep. 14: 1302-1308Reddy V.Y. Holmes D. Doshi S.K. Neuzil P. Kar S.

Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.

Circulation Feb 1. 123: 417-424Jhand A. Thandra A. Gwon Y. et al.

Intracardiac echocardiography versus transesophageal echocardiography for left atrial appendage closure: an updated meta-analysis and systematic review.

American journal of cardiovascular disease. 10: 538-547Tan B.E. Boppana L.K.T. Abdullah A.S. Chuprun D. Shah A. Rao M. Bhatt D.L. Depta J.P.

Safety and Feasibility of Same-Day Discharge After Left Atrial Appendage Closure With the WATCHMAN Device.

Circ Cardiovasc Interv Jan. 14e009669Gilhofer T.S. Inohara T. Parsa A. Walker M. Uchida N. Tsang M. Saw J.

Safety and Feasibility of Same-Day Discharge After Left Atrial Appendage Closure.

Can J Cardiol Jun. 36: 945-947Connolly S.J. Eikelboom J. Joyner C. et al.

Apixaban in patients with atrial fibrillation.

N Engl J Med Mar 3. 364: 806-817Mant J. Hobbs F.D. Fletcher K. Roalfe A. Fitzmaurice D. Lip G.Y. Murray E. investigators B. Midland Research Practices N.

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Lancet. 370: 493-503

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet Mar 15 2014;383:955-962.

Osmancik P. Herman D. Neuzil P. et al.

Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.

J Am Coll Cardiol Jun 30. 75: 3122-3135